Advances in virtual screening
暂无分享,去创建一个
[1] Dan C. Fara,et al. Integration of virtual and physical screening , 2006, Drug Discovery Today: Technologies.
[2] Andrew Potter,et al. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. , 2006, Bioorganic & medicinal chemistry.
[3] Prasad V. Bharatam,et al. New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies , 2006, J. Comput. Aided Mol. Des..
[4] Wolfgang Guba,et al. Integrating molecular design resources within modern drug discovery research: the Roche experience. , 2006, Drug discovery today.
[5] Matthias Rarey,et al. Small Molecule Docking and Scoring , 2001 .
[6] T. Langer,et al. Strategies for efficient lead structure discovery from natural products. , 2006, Current medicinal chemistry.
[7] Dariusz Plewczynski,et al. Assessing Different Classification Methods for Virtual Screening , 2006, J. Chem. Inf. Model..
[8] Victor A Kenyon,et al. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. , 2006, Journal of medicinal chemistry.
[9] Robert P Sheridan,et al. Why do we need so many chemical similarity search methods? , 2002, Drug discovery today.
[10] Thierry Langer,et al. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.
[11] Alexander Golbraikh,et al. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. , 2004, Journal of medicinal chemistry.
[12] Artem Cherkasov,et al. Successful in silico discovery of novel nonsteroidal ligands for human sex hormone binding globulin. , 2005, Journal of medicinal chemistry.
[13] Peter Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.
[14] Haralambos Sarimveis,et al. Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques , 2006, J. Comput. Aided Mol. Des..
[15] Tudor I. Oprea,et al. Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.
[16] Y. Martin,et al. Challenges and prospects for computational aids to molecular diversity , 1996 .
[17] Gisbert Schneider,et al. Ligand-based combinatorial design of selective purinergic receptor (A2A) antagonists using self-organizing maps. , 2003, Journal of combinatorial chemistry.
[18] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[19] Michal Vieth,et al. SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy. , 2004, Journal of medicinal chemistry.
[20] G. Schneider,et al. Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. , 2005, Journal of medicinal chemistry.
[21] Yovani Marrero-Ponce,et al. Ligand-Based Virtual Screening and in Silico Design of New Antimalarial Compounds Using Nonstochastic and Stochastic Total and Atom-Type Quadratic Maps , 2005, J. Chem. Inf. Model..
[22] Antti Poso,et al. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.
[23] Brian K. Shoichet,et al. Virtual Screening in Drug Discovery , 2005 .
[24] A Good,et al. Structure-based virtual screening protocols. , 2001, Current opinion in drug discovery & development.
[25] Anil K. Saxena,et al. Evaluation of Binary QSAR Models Derived from LUDI and MOE Scoring Functions for Structure Based Virtual Screening , 2006, J. Chem. Inf. Model..
[26] Thy-Hou Lin,et al. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. , 2006, Journal of medicinal chemistry.
[27] Qiang Zhang,et al. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.
[28] Paolo Bonvini,et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.
[29] Y. Martin,et al. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.
[30] Andrew C. Good,et al. Three‐Dimensional Structure Database Searches , 2007 .
[31] D. Faller,et al. Identification of Novel Small‐molecule Inducers of Fetal Hemoglobin Using Pharmacophore and ‘PSEUDO’ Receptor Models , 2006, Chemical biology & drug design.
[32] Wolfgang Guba,et al. Focused library design in GPCR projects on the example of 5‐HT2c agonists: Comparison of structure‐based virtual screening with ligand‐based search methods , 2005, Proteins.
[33] Matthias Rarey,et al. Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..
[34] Tudor I. Oprea,et al. Virtual and biomolecular screening converge on a selective agonist for GPR30 , 2006, Nature chemical biology.
[35] Manfred E. Wolff,et al. Burger's Medicinal chemistry , 1980 .
[36] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[37] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[38] Richard A Ward,et al. Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. , 2005, Journal of medicinal chemistry.
[39] Yvonne C. Martin,et al. Searching Databases of Three‐Dimensional Structures , 2007 .
[40] Alexander Tropsha,et al. Application of validated QSAR models of D1 dopaminergic antagonists for database mining. , 2005, Journal of medicinal chemistry.
[41] Rick Mullin,et al. DRUG DISCOVERY: As high-throughput screening draws fire, researchers leverage science to put automation into perspective , 2004 .
[42] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.
[43] 山下 伸二,et al. Virtual Screening を目指した薬物動態研究 , 2002 .
[44] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[45] William Ng,et al. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. , 2005, Journal of medicinal chemistry.
[46] Thomas Lengauer,et al. Multiple-ligand-based virtual screening: methods and applications of the MTree approach. , 2005, Journal of medicinal chemistry.
[47] Tudor I. Oprea,et al. Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.
[48] Yi Li,et al. Analysis and optimization of structure-based virtual screening protocols. 2. Examination of docked ligand orientation sampling methodology: mapping a pharmacophore for success. , 2003, Journal of molecular graphics & modelling.
[49] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[50] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[51] I. Lu,et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.
[52] Rick Mullin,et al. PRIMING THE PIPELINE , 2004 .